PreS2/S vaccination of chronic hepatitis B virus (HBV) carriers led to a reduction in HBV replication or clearance of virus in 30 % of treated patients. This study assessed whether vaccinotherapy of chronic HBV carriers induced the selection of escape mutants in the envelope ' a ' determinant and whether envelope genetic variability might affect the response to vaccination. No amino acid differences were observed in the ' a ' determinant between sequences obtained before and after treatment (five responders and seven nonresponders). However, alignment with HBV prototype sequences revealed seven amino acid changes. Two mutations (T140S and P127L) diverged from subtype variations. In the complete envelope sequence (five non-responders and five responders), ten amino acid modifications were detected between sequences obtained before and after treatment. The absence of any common mutations did not enable the definition of a hot spot of mutations implicated in the response to vaccination. Moreover, vaccinotherapy does not induce the selection of escape mutants in the ' a ' determinant.
PreS2/S vaccination of chronic hepatitis B virus (HBV) carriers led to a reduction in HBV replication or clearance of virus in 30 % of treated patients. This study assessed whether vaccinotherapy of chronic HBV carriers induced the selection of escape mutants in the envelope ' a ' determinant and whether envelope genetic variability might affect the response to vaccination. No amino acid differences were observed in the ' a ' determinant between sequences obtained before and after treatment (five responders and seven nonresponders). However, alignment with HBV prototype sequences revealed seven amino acid changes. Two mutations (T140S and P127L) diverged from subtype variations. In the complete envelope sequence (five non-responders and five responders), ten amino acid modifications were detected between sequences obtained before and after treatment. The absence of any common mutations did not enable the definition of a hot spot of mutations implicated in the response to vaccination. Moreover, vaccinotherapy does not induce the selection of escape mutants in the ' a ' determinant.
The human hepatitis B virus (HBV) is a DNA virus that causes chronic infections that frequently lead to the development of cirrhosis and cellular hepatocellular carcinoma (Chisari & Ferrari, 1995) . Antiviral therapies such as interferon-α stably inhibit HBV replication in about 20-30 % of chronic carriers (Niederau et al., 1996 ; Wright & Lau, 1993) . Nucleoside analogues such as lamivudine have exhibited highly effective antiviral activity, but mutations in the viral genome are frequently associated with a recurrence of HBV replication (Fontaine et al., 1999 ; Zoulim & Trepo, 1999) . In this context, a new approach to HBV treatment has been proposed, Author for correspondence : Dina Kremsdorf.
Fax j33 1 40 61 55 81. e-mail kremsdor!necker.fr consisting of immunotherapy using vaccination with recombinant envelope proteins (Pol et al., 1994 (Pol et al., , 2000 . Clinical trials have suggested a reduction of at least 50 % or clearance of HBV replication in about 30 % of chronic HBV carriers 3 months after three monthly doses of S (Recombivax) or preS2\S (GenHevac B) vaccines (Pol et al., 1994 (Pol et al., , 2000 . This is reinforced further by an induction of the CD4 + T cell response during this treatment (Couillin et al., 1999) . Other vaccine strategies based on single-epitope CTL or HBV vaccine and anti-HBs complex have been also envisaged (Heathcote et al., 1999 ; Wen et al., 1995) .
It is well established that HBV surface antigen (HBsAg) is a major target of the humoral and cellular immune response against HBV. Within HBsAg, the ' a ' determinant is an important target of the humoral immune response (Brown et al., 1984) . The antigenic ' a ' determinant (residues 124-147) has a highly conformational structure that consists of two loops held by disulphide bridges (cysteines 124-137 and 139-147) projecting from the virus surface (Brown et al., 1984) . In recent years, envelope mutants have been detected following vaccination or anti-HBs immunoglobulin therapy. Vaccine-associated HBsAg mutations have principally been identified in the ' a ' determinant (Carman et al., 1993) . These mutants, possibly selected under vaccine pressure, may escape neutralization by vaccine-induced anti-HBs (Hsu et al., 1999) . However, such HBV mutants are also present in chronic, asymptomatic HBV carriers. The most frequently identified mutation is the glycine-to-arginine change at position 145 of HBsAg (Carman et al., 1990 (Carman et al., , 1993 . This mutation has, in particular, been identified in HBV-infected children vaccinated against HBV and living in regions of virus endemicity (Oon et al., 1995) . Amino acid changes have been also identified in the ' a ' determinant in liver transplant recipients treated with monoclonal or polyclonal anti-HBs immunoglobulin (Carman et al., 1996 ; McMahon et al., 1992 ; Protzer-Knolle et al., 1998) .
HBV vaccination of chronic HBV carriers is a promising therapeutic strategy. However, an important issue when designing future trials is to assess whether vaccine therapy in HBV chronic carriers may induce the selection of escape mutants. In this context, the aim of this study was to determine whether the vaccination of chronic HBV carriers would induce 
the selection of a mutant in the antigenic ' a ' determinant and whether HBV envelope genetic variability might affect the response of chronic carriers to vaccination. The 19 patients investigated have participated in a pilot clinical study concerning the vaccination of 32 chronic HBV carriers with active HBV replication (Pol et al., 1994) . Vaccination consisted of three intramuscular injections of GenHevac B (HBsAg and pre-S2 protein, Pasteur-Me! rieux) at 1-month intervals. The response to vaccinotherapy was defined by a reduction of at least 50 % of serum HBV DNA 3 months after the last injection (tested by using the Quantiplex bDNA branch or Murex kit).
HBV serological markers, virus load and sequence analysis of the antigenic ' a ' determinant were studied in 12 patients (five responders and seven non-responders) before and 6 and\or 12 months after vaccinotherapy (Table 1 ; Fig. 1 ). The HBV serological pattern of patients was assessed by using a standard enzyme immunoassay (Abbott). All patients were HBsAg-and hepatitis B e antigen (HBeAg)-positive before vaccinotherapy. Anti-HBe was detected in four of five responders (Table 1) . For the last responder patient (no. 21), anti-HBe was detected 21 months after initiation of treatment (data not shown). HBV sequences of the antigenic ' a ' determinant were compared first with HBV subtypes (Fig. 1) . Eight of the sequences were related to the adw2 subtype (cases 3, 12, 17, 21, 22, 24, 29 and 30) and four to the ayw2 subtype (cases 5, 10, 16 and 50). A response to vaccination was observed in patients infected with the ayw (2\4) and adw (3\8) subtypes. Vaccine therapy was undertaken with the GenHevac B vaccine (Pasteur-Me! rieux) containing HBs and preS2 proteins from the ayw subtype. The sequence data thus demonstrated that a response to vaccination was independent of the infecting strain. This agreed with previous findings, demonstrating that the epitopes recognized after vaccinotherapy are present in conserved regions of the proteins (Couillin et al., 1999) . No differences were observed in the sequences obtained before and after treatment from any of the patients, whether or not they responded to vaccination (Fig. 1) . This result suggests that vaccinotherapy does not induce the emergence of escape mutants in the ' a ' antigenic determinant.
When the ' a ' determinant sequences obtained before and after vaccination were compared with ayw2 and adw2 subtype sequences, amino acid variations were observed in the sequences of three non-responders (nos 5, 10 and 30) and one responder (no. 21) (Fig. 1) . Five of seven substitutions corresponded to amino acid changes from subtype ayw2 to ayw3 or adw2 (M125T and P127T for patient 10 ; Y134F for patient 5) or from subtype adw2 to ayw (N131T for patients 21 and 30 ; T143S for patient 30). Amino acid changes P127T, N131T and Y134F have been described previously as being involved in d\y subtype specificity (Gerin et al., 1983) . Substitutions M125T and T143S have been described previously ; however, these were not thought to be important for ayw\adw subtype specificity but, rather, to reflect genotype variations (Norder et al., 1993 ; Protzer-Knolle et al., 1998) . In addition, P127T, Y134F and T143S substitutions were also observed in livers of transplanted patients reinfected despite hepatitis B immune globulin prophylaxis (Ghany et al., 1998) . In two non-responder patients (nos 5 and 30), the observed amino acid changes (T140S for both patients ; P127L for patient 30) have not been assigned to subtype variations. However, these substitutions have been reported in E and F strains originating in aboriginal populations of Africa and the DGI HBV preS2/S vaccination and virus sequences HBV preS2/S vaccination and virus sequences Fig. 1 . Amino acid sequences of the antigenic ' a ' determinant of non-responder (NR) and responder (R) patients, before (M0) and 6 (M6) and/or 12 (M12) months after vaccination. After PCR amplification of the HBV envelope gene from serum with sense and antisense primers 5h CTGCAGGGGTCACCATATTCTTGG 3h (2812-2837) and 5h GACATACTTTCCAATCAATA 3h (895-876), direct sequencing was performed by using HBV envelope internal primers (Gerken et al., 1991) . Samples from three responders, obtained 1 year after vaccination, failed to be amplified. The sequence at the top corresponds to ayw2 or adw2 HBV and numbers indicate the amino acid position in the major S antigen. The single letter code for amino acids is used. Homologous amino acids from the M0 sequence are indicated by dashes. Underlined amino acids correspond to variations compared with HBV subtype ayw2 or adw2.
New World, respectively (Magnius & Norder, 1995 ; Norder et al., 1993 ; Protzer-Knolle et al., 1998) . In addition, substitution T140S has been defined previously as an escape mutant in transplanted HBV chronic carriers (McMahon et al., 1992) . In order to determine whether these two mutations (present in two of seven non-responders) could be implicated in a nonresponse phenotype, we performed sequence analyses on seven additional non-responder patients 1 year after the beginning of the trial. Neither the P127L and T140S substitutions, nor changes independent of subtype variation, were observed. Thus, these variations are probably not involved in the non-responder pattern. However, further study with a larger number of patients will be necessary to confirm this finding.
In order to investigate the potential role of HBV genetic variability outside the antigenic ' a ' determinant in the response to vaccination, the complete sequences of the envelope proteins of five non-responders and five responders were obtained before and 6 months after vaccination. Table 2 summarizes the genetic variations observed when the pre-and post-treatment sequences were compared. A total of ten amino acid changes were observed in six patients. These changes were detected regardless of the response to treatment.
However, the same amino acid change was never seen in more than one patient. Thus, we could not define a specific domain implicated in the response to vaccinotherapy. In one patient, the mutation at position 216 in the S domain introduced a stop codon, deleting the last 11 amino acids of the envelope protein.
Two substitutions (S115T in preS1 and T54P in preS2) corresponded to subtype variations. Amino acid changes G16D, T55A in preS1 and Q122K in the S domain corresponded to a reversion to a wild-type sequence. The variation at position 122 in the S domain has been described previously as being important for the recognition of antibodies against the d\y subtype epitope (Okamoto et al., 1989) . This type of reversion from mutated to wild-type HBsAg had been reported between a mother and her vaccinated child (Chong-Jin et al., 1999) . The last four mutations (H60P, Q89R and P96T in preS1 and E164G in S) did not correspond to subtype variations. Two of these substitutions (Q89R and P96T), identified in two responder patients, were located in preS1 domains involved in the B cell response. The E164G mutation located in the S domain was observed in a non-responder patient. The implications of this amino acid change as an escape mutant require further investigation.
In conclusion, our data highlight two important pieces of DGJ P. Soussan and others P. Soussan and others 
information. Firstly, vaccinotherapy did not select escape mutants in the antigenic ' a ' determinant. However, it cannot be excluded that, in some patients, pre-existing mutations in the ' a ' determinant may play a role in the response to vaccination. Secondly, outside the ' a ' determinant, our study identified a number of amino acid substitutions (mostly located in preS1) following vaccination. The absence of common mutations did not allow us to define a hot spot for mutations implicated in the pattern of response to vaccinotherapy. The amino acid substitution pattern observed during this short period (6 months) in the complete envelope sequence could be consistent with an attempt by the virus to escape from the pressure induced after vaccination. Collectively, such investigations should contribute to the understanding of the basis of active immunotherapy of HBV chronic carriers.
